pravastatin has been researched along with Hyperlipemia in 207 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.97) | 18.7374 |
| 1990's | 77 (37.20) | 18.2507 |
| 2000's | 99 (47.83) | 29.6817 |
| 2010's | 27 (13.04) | 24.3611 |
| 2020's | 2 (0.97) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, S; Hosomi, N; Kagimura, T; Kitagawa, K; Maruyama, H; Matsumoto, M; Minematsu, K; Nagai, Y; Nakagawa, Y; Nezu, T; Origasa, H; Uchiyama, S | 1 |
| Abeydeera, D; Demer, LL; Fong, F; Iriana, S; Lu, M; Patel, NR; Qiao, R; Tintut, Y; Xian, JZ | 1 |
| Gao, JH; Lu, JL; Wang, HM | 1 |
| Ahn, CM; Chang, HJ; Choi, D; Chun, KH; Ha, JW; Hong, GR; Hong, MK; Jang, Y; Kang, M; Kang, SM; Kim, BK; Kim, JS; Ko, YG; Lee, CJ; Lee, SH; Oh, J; Park, S; Roh, JW; Shim, CY | 1 |
| da Silva, LCN; de Barros Gomes, E; de Miranda, RCM; Dias, LRL; Neto, RNM; Weba-Soares, L | 1 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Boukari, L; Fain, O; Glitho, S; Mekinian, A | 1 |
| Baimbridge, C; Barzilay, JI; Basile, JN; Davis, BR; Henriquez, MA; Huml, A; Kopyt, N; Louis, GT; Pressel, SL; Rahman, M; Rosendorff, C; Sastrasinh, S; Stanford, C | 1 |
| Chen, W; Jiang, Y; Li, P; Lin, N; Lu, C; Xu, Y; Zhang, H; Zhang, Y; Zhu, B | 1 |
| Glasziou, PP; Irwig, L; Kirby, AC; Simes, RJ; Tonkin, AM | 1 |
| Campbell, SE; Davidson, MH; Kryzhanovski, VA; Morgan, RE; Sponseller, CA | 1 |
| Banefelt, J; Fox, KM; Gandra, SR; Hallberg, S; Johansson, G; Levin, LÅ; Mesterton, J; Sobocki, P | 1 |
| D'Agostino, RB; Jones, SR; Joshi, PH; Martin, SS; Massaro, JM; Miller, PE; Sponseller, CA; Toth, PP | 1 |
| He, F; Li, HW; Li, SX; Liu, TN; Wu, CT; Wu, M; Yu, HY; Yuan, W | 1 |
| Añino Alba, A; Fernandez-Esteban, I; Fernandez-Tabera, JM; Gómez Álvarez, P; Izquierdo-Palomares, JM; Martin-Carrillo, P; Pinar López, Ó; Plana, MN; Saiz, LC | 1 |
| Hosomi, N; Kitagawa, K; Koga, M; Matsumoto, M; Minematsu, K; Nagai, Y; Origasa, H; Toyoda, K; Uchiyama, S; Yasaka, M | 1 |
| Barrett, DA; Bruce, KD; de Moor, CH; Eckel, RH; Gershkovich, P; Lee, JB; Sungelo, M; Taha, DA; Zgair, A | 1 |
| Burne-Taney, MJ; Ikeda, M; Ito, K; Kumagai, K; Mori, M; Rabb, H; Sharyo, S; Uchida, K; Yokota-Ikeda, N | 1 |
| Hata, M; Hirayama, A; Minami, K; Sezai, A; Takayama, T; Yoshitake, I | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J | 1 |
| Becker, DJ; Farrar, JT; French, B; Gordon, RY; Halbert, SC; Morris, PB; Rader, DJ; Schmitz, K; Thompson, PD | 1 |
| Strandberg, TE | 1 |
| Bryniarski, L; Ducobu, J; Farnier, M | 2 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 2 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Bryniarski, L; Császár, A; De Niet, S; Ducobu, J; Farnier, M; Marcereuil, D; Retterstøl, K; Steinmetz, A; Vanderbist, F | 1 |
| Farnier, M | 2 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Huang, C; Huang, Z; Jiang, H; Wu, G; Xie, Q; Xu, L | 1 |
| Iketani, T; Takazawa, K; Yamashina, A | 1 |
| Ito, T; Kushihata, S; Masaki, T; Nishida, Y; Oda, H; Taniguchi, Y; Yamakido, M; Yorioka, N | 1 |
| DeGruiter, H; Lavie, CJ; Mehra, MR; Milani, RV; Uber, PA; Vivekananthan, K | 1 |
| Irons, BK; MacLaughlin, EJ; McCall, K; Snella, KA; Villarreal, M | 1 |
| Almenar Bonet, L; Arnau Vives, MA; Dicenta Gisbert, F; Martínez-Dolz, L; Osa Sáez, A; Palencia Pérez, M; Rueda Soriano, J | 1 |
| Mehta, JL; Singh, BK | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ; Vernalis, MN | 1 |
| SoRelle, R | 1 |
| Császár, A; Márk, L | 1 |
| Blazing, MA; Duvall, WL; Guyton, JR; Saxena, S | 1 |
| Aronov, DM; Bubnova, MG; Golubev, MA; Mel'kina, OE; Olfer'ev, AM; Perova, NV; Zhasminova, VG | 1 |
| Ducobu, J; Salomon, H; VanHaelst, L | 1 |
| Clark, LT | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Achimastos, A; Bairaktari, E; Elisaf, M; Ganotakis, E; Hasiotis, G; Kostoula, A; Mikhailidis, DP; Rizos, E | 1 |
| Betz, W; Devroey, D; Duquet, W; Velkeniers, B | 1 |
| Lee, SJ; Sacks, FM | 1 |
| Awasthi, A; Guido, JJ; Kalaria, VG; Mackin, ML; Pearson, TA; Rains, A; Schwartz, RG; Shah, A; Williford, DJ | 1 |
| Diener, HC | 1 |
| Arulchelvam, M; Baker, J; Beller, E; Best, J; Colquhoun, D; Hague, W; Hunt, D; Keech, A; Kirby, A; Simes, RJ; Tonkin, A | 1 |
| Ito, MK | 1 |
| Ikeda, S; Ishii, K; Matsushima, T; Miya, F; Shoji, S; Tamaoka, A; Tokuda, T | 1 |
| Aller, R; Bachiller, P; de Luis, DA; Eiros Bouza, J; Izaola, O | 1 |
| Galper, JB; Kim, YJ; Park, HJ; Saul, JP; Shin, DG; Welzig, CM | 1 |
| Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A | 1 |
| Kiniwa, M; Matsuura, N; Ohmori, K; Yamada, H; Yamamoto, A; Yasuda, A | 1 |
| Quiroz, Y; Rodríguez-Iturbe, B; Sato, T; Vaziri, ND | 1 |
| Arai, M; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Nishigaki, K; Okubo, M; Sano, K; Takemura, G; Uno, Y; Yokoyama, H | 1 |
| Pasternak, RC; Skerrett, PJ | 1 |
| Bilchick, KC; Blumenthal, RS; Henrikson, CA; Kasper, EK; Skojec, D | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Farmer, JA | 2 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| de Grooth, GJ; Kastelein, JJ; Kawamura, H; Klerkx, AH; Kuivenhoven, JA; Trip, MD; Wilhelm, F | 1 |
| Kawamori, R; Miwa, S; Nishiyama, K; Omura, C; Onuma, T; Takayanagi, N; Tanaka, Y; Watada, H | 1 |
| Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S | 1 |
| Hata, T; Ishikawa, K; Kitagawa, Y; Ohta, T; Shinohara, Y; Tomiyasu, H; Yamamoto, M | 1 |
| Curhan, G; Jhangri, GS; Pfeffer, M; Sacks, F; Tonelli, M | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pocaterra, D; Sebastiani, T; Tampellini, L | 1 |
| Fujita, H; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Murata, I; Okubo, M; Sano, K; Tsuchiya, K; Yokoyama, H; Zhou, X | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Kawaguchi, A; Mitsudo, K; Nobuyoshi, M; Yamamoto, A; Yokoi, H | 1 |
| Inaba, T; Kato, M; Kitayama, K; Koike, H; Mizuno, M; Sada, T | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Evans, SR; Fichtenbaum, CJ; Glesby, MJ; Henry, WK; Owens, SI; Torriani, FJ; Yang, Y; Zackin, RA | 1 |
| Caspard, H; Chan, AK; Walker, AM | 1 |
| Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M | 1 |
| Chen, J; Chu, JM; Huang, Y; Huang, YL; Li, JJ; Li, YS; Wang, Y; Yuan, JQ; Zhang, CY | 1 |
| Hingorani, A; Humphries, SE | 1 |
| Eschert, H; Hofnagel, O; Luechtenborg, B; Robenek, H; Severs, NJ; Weissen-Plenz, G | 1 |
| Kawasaki, A; Kesler, A; Purvin, V; Smith, KH | 1 |
| Apperson-Hansen, C; Churchill, T; Crowe, T; Lin, S; Loyd, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wang, C; Wolski, K | 1 |
| Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G | 1 |
| Coleman, CI; Dale, KM; Kluger, J; Patel, AA; Shah, SA; White, CM | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Adachi, M; Hayashi, T; Hirano, T; Ito, Y; Mori, Y; Nagashima, M; Shiraishi, Y; Tokuno, A; Yamamoto, T | 1 |
| Dagli, N; Karaca, I; Yavuzkir, M | 1 |
| Bhalodia, J; Hollowell, SB; Johnson, MD; Kaye, KS; Townsend, ML; Wilson, KH | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Fukami, M; Fukushige, J; Hosokawa, T; Ito, T; Shiomi, M; Tamura, A; Tsujita, Y; Tsukada, T; Watanabe, Y; Yata, T | 1 |
| Cooper, ME; Jerums, G; Panagiotopoulos, S; Sinha, A; Tsalamandris, C | 1 |
| Miwa, I; Onaya, T; Ozawa, M; Shindo, H; Tawata, M; Tsuchiya, K; Wakasugi, M | 1 |
| Miettinen, TA; Vanhanen, HT | 1 |
| Shepherd, J | 1 |
| Akabane, S; Inoue, I; Ishii, J; Katayama, S; Kawazu, S; Negishi, K; Suzuki, M; Takahashi, K | 1 |
| Carmena, R | 1 |
| Boni, M; De Sio, G; Mazzanti, L; Monteburini, T; Polenta, M; Testa, I | 1 |
| Erkelens, DW; Illingworth, DR; Keller, U; Thompson, GR; Tikkanen, MJ | 1 |
| Rosenson, RS; Stein, JH | 1 |
| Cremer, P; Seidel, D | 1 |
| Gørbitz, C; Malt, UF; Ose, L; Tonstad, S | 1 |
| al'Halawani, MH; Frisbie, K; Larsen, JL; Miller, S; Stratta, RJ; Taylor, RJ | 1 |
| Frauenheim, WA; Rosenson, RS | 1 |
| Ishimoto, F; Matsuda, H; Matsumoto, H; Misawa, T; Nakano, H; Ohno, I; Sakai, O; Shibasaki, T | 1 |
| Ito, T; Shiomi, M | 1 |
| Tsujita, Y | 1 |
| Cattran, D; Porush, JG; Spitalewitz, S; Wright, N | 1 |
| Hattori, M; Ito, K; Kawaguchi, H; Khono, M; Kubota, R; Tanaka, T | 1 |
| Martínez-Castelao, A | 1 |
| Dobs, AS; Goldberg, A; Guccione, M; Hoover, DR; Prasad, M | 1 |
| Feingold, KR; Marcelino, JJ | 1 |
| Darioli, R; Greminger, P; Riesen, W; Simeon-Dubach, D; Waeber, B; Wunderlin, R | 1 |
| Simons, LA | 1 |
| Ballantyne, CM; Bourge, RC; Domalik, LJ; Eisen, HJ; Fishbein, DP; Kubo, SH; Lake, KD; Radovancevic, B; Taylor, DO; Ventura, HO; Yancy, CW; Young, JB | 1 |
| Evéquoz, D | 1 |
| Busuttil, RW; Dawson, S; Goldstein, LI; Holt, CD; Imagawa, DK; Kaldas, FM; Kinkhabwala, MM; Kirk, PS; Martin, P; Murray, NG; Rudich, SM; Seu, P; Shackleton, CR; Terasaki, PI | 1 |
| Mafauzy, M; Mokhtar, M; Musalmah, M; Wan Mohamad, WB | 1 |
| DerFler, K | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Aguilar-Salinas, CA; Barrett, R; Hugh, P; Pulai, J; Schonfeld, G; Zhu, XL | 1 |
| Braesen, JH; Harsch, M; Niendorf, A | 1 |
| Barretto, AC; Bellotti, G; do Serro Azul, JB; Gebara, OC; Nussbacher, A; Pierri, H; Pileggi, F; Pivotto, L; Wajngarten, M | 1 |
| Amelineau, E; Berthezène, F; Desriac, I; Krempf, M; Moinade, S; Passa, P; Wemeau, JL | 1 |
| Fogari, R; Lusardi, P; Marasi, G; Preti, P; Vanasia, A; Zoppi, A | 1 |
| Grundy, SM; Mostaza, JM; Schulz, I; Vega, GL | 1 |
| Durrington, P | 2 |
| Katznelson, S | 1 |
| Bönner, G | 1 |
| Adkins, JC; Faulds, D | 1 |
| Doi, Y; Kitazoe, Y; Kurihara, Y; Narita, Y; Okuhara, Y; Saito, N; Takamatsu, K | 1 |
| Gotto, AM | 1 |
| Mabuchi, H | 1 |
| Fuyuki, T; Horiguchi, F; Komukai, S; Makita, K; Nozawa, S; Ohta, H; Sugimoto, I; Takamatsu, K | 1 |
| Bräsen, JH; Harsch, M; Niendorf, A | 1 |
| Serizawa, N | 1 |
| Anand, R; Burrows, L; Genyk, Y; Knight, R; Moran, V; Schwartz, B | 1 |
| Hamazaki, T; Jokaji, H; Kobayashi, M; Minami, S; Nakamura, N | 1 |
| Ascher, NL; Ferrell, LD; Harihara, Y; Hashikura, Y; Inoue, Y; Kakizoe, S; Kawarasaki, H; Kawasaki, S; Kita, Y; Kiyosawa, K; Kubota, K; Lake, JR; Makuuchi, M; Mori, M; Ohtake, T; Ohtomo, K; Oka, T; Roberts, JP; Shiga, J; Takayama, T; Takikawa, H; Tanaka, E; Yotsuyanagi, H | 1 |
| Coronado, M; Escola, JM; Robles, NR; Ruiz-Calero, R; Sánchez Casado, E | 1 |
| Iliadis, EA; Rosenson, RS | 1 |
| Ambrose, JA; Badimon, JJ; Dangas, G; Fallon, JT; Fier, C; Levine, D; Meraj, P; Shao, JH; Smith, DA; Unger, AH | 1 |
| López Miranda, J; Pérez Jiménez, F; Zambrana García, JL | 1 |
| de Maat, MP; Gevers Leuven, JA; Kluft, C; Mohrschladt, MF; Potter van Loon, BJ | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Basile, V; Capone, D; Gentile, A; Imperatore, P; Pellegrino, T; Stanziale, P | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Abe, K; Imai, Y; Saito, T; Saruta, T; Suzuki, H; Tsuji, I | 1 |
| Cicco, G; Pirrelli, A; Stingi, GD; Tarallo, MS; Vicenti, P | 1 |
| Hsu, JC; Kashyap, ML; Sikand, G; Wong, ND | 1 |
| Garrido Sanjuán, JA; González González, C; Pía Iglesias, G; Sesma Sánchez, P | 1 |
| Branzi, A; Carinci, V; Magelli, C; Magnani, G; Potena, L; Reggiani, LB | 1 |
| Chien, KC; Inoue, M; Kasahara, E; Ohnishi, Y; Suzumura, K | 1 |
| Ammassari, A; Baldini, F; Cingolani, A; De Luca, A; Di Giambenedetto, S; Murri, R | 1 |
| Lauterbach, KW | 1 |
| Chu, CW; Hsiao, CL; Lee, BC; Lee, TM; Su, SF | 1 |
| Fuyuki, T; Horiguchi, F; Makita, K; Masuda, A; Nozawa, S; Ohta, H; Suda, Y; Sugimoto, I; Takamatsu, K | 1 |
| Su, DH; Yeo, KT | 1 |
| Ikeda, A; Ueki, M; Ushiroyama, T | 1 |
| Aikawa, M; Enomoto, M; Fukumoto, Y; Hill, CC; Hirouchi, Y; Libby, P; Rabkin, E; Shiomi, M | 1 |
| Kast, RE | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D | 1 |
| Fricker, FJ; Harker, K; Kahler, DA; Penson, MG; Schowengerdt, KO; Thompson, JR; Williams, BJ | 1 |
| Beynen, AC; Donker, AJ; Heine, RJ; Rustemeijer, C; Schouten, JA; Voerman, HJ | 1 |
| De Gevigney, G; Delahaye, F | 1 |
| Jackson, G | 1 |
| Bacharaki, D; Bamichas, G; Grekas, D; Kassimatis, E; Makedou, A; Tourkantonis, A | 1 |
| Fujimura, A; Harada, K; Tsuruoka, S | 1 |
| Le, NA | 1 |
| Dresselhaus, TR; Henry, RR; Ito, MK; Lin, JC; Marcus, DB; Morreale, AP; Shabetai, R | 1 |
| Faust, M; Kotzka, J; Krone, W; Müller-Wieland, D | 1 |
| Bazalo, GR | 1 |
| Chou, TF; Lee, TM; Su, SF; Tsai, CH | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Jialal, I; Stein, DT | 1 |
| Liew, D; Lim, SS; McNeil, JJ; Peeters, A; Vos, T | 1 |
| Stein, EA | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Jick, H; Kaye, JA; Meier, CR; Walker, AM | 1 |
| Bourgeois, J; Després, JP; Dzavik, V; Laperrière, L; Lemieux, I; Tremblay, G | 1 |
| Itakura, H | 2 |
| Conner, WT; Cullen-Dean, G; Helden, E; McCrindle, BW | 1 |
| Mach, F | 1 |
| Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C | 1 |
| Fujinami, T; Ichikawa, T; Iwata, S; Sakuma, N | 1 |
| AlHinai, A; Amorosa, LF; Ananthakrishnan, R; Coly, E; Khachadurian, AK; Martucci, C; Rozovski, SJ; Schneider, SH; Shimamura, T | 1 |
| Altona, B; Anderson, GW; Benkenstein, TM; Bennett, JM; Bhoola, RL; Blake, TA; Blomerus, P; Botha, AP; Branken, TI; Steingo, L | 1 |
| Toyota, T | 1 |
| Fukami, M; Fukushige, J; Itakura, H; Ito, T; Kuroda, M; Matsumoto, A; Nara, F; Shiomi, M; Tsujita, Y; Watanabe, Y | 1 |
| Furuta, S; Higuchi, M; Hora, K; Miyasaka, M; Oguchi, H; Terashima, M; Tokoo, M; Tokunaga, S; Yoshie, T | 1 |
| Illingworth, DR | 1 |
| Kawagishi, T; Morii, H; Nishizawa, Y; Okuno, Y; Shoji, T; Toyokawa, A | 1 |
| alHinai, A; Amorosa, LF; Ananthakrishnan, R; Armenian, B; Coly, E; Khachadurian, AK; Martucci, C; Rozovski, SJ; Schneider, SH; Shimamura, T | 1 |
| Mimura, K; Yukawa, S | 1 |
| Horiuchi, I; Kajiyama, G; Mizuno, T; Ohya, T; Takizawa, I; Tazuma, S | 1 |
| Berrocal, M; Chang, S; Drexler, A; Gordon, B; Kavanagh, M; Robertson, C; Yannuzzi, L | 1 |
| Furukawa, S; Hirano, T; Komuro, F; Nagano, S; Takahashi, T | 1 |
| Brown, WV; Karmally, W; Smith, DA | 1 |
| Inui, A; Iwai, M; Iwatani, I; Kasama, T; Kazumi, T; Matsuba, K; Otsuki, M; Uenoyama, R; Yokono, K; Yoshino, G | 1 |
36 review(s) available for pravastatin and Hyperlipemia
| Article | Year |
|---|---|
Biotechnological Production of Statins: Metabolic Aspects and Genetic Approaches.
Topics: Animals; Biotechnology; Fermentation; Fungi; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Metabolic Engineering; Pravastatin | 2019 |
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Drug Chronotherapy; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Pravastatin; Risk Factors; Triglycerides | 2012 |
Update on the management of dyslipidemia.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Assessment; Risk Factors | 2002 |
Management of dyslipidemia in the primary prevention of coronary heart disease.
Topics: Animals; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2002 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Role of the pharmacist in establishing lipid intervention programs.
Topics: Clinical Trials as Topic; Humans; Hyperlipidemias; Pharmacies; Pharmacists; Pharmacy Service, Hospital; Pravastatin; Program Development; Simvastatin; United States | 2003 |
ALLHAT-LLT: questions, questions, and more questions (and some answers).
Topics: Aged; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pravastatin; Risk | 2004 |
Treatment of hyperlipidemia in cardiac transplant recipients.
Topics: Algorithms; Coronary Artery Disease; Endothelium, Vascular; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Pravastatin; Simvastatin | 2004 |
Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease.
Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Clinical Trials as Topic; Coronary Disease; Cytochrome P-450 CYP2C9; Genetic Testing; Genotype; Hemorrhage; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Warfarin | 2006 |
Statin-associated myasthenia gravis: report of 4 cases and review of the literature.
Topics: Aged; Autoantibodies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myasthenia Gravis; Pravastatin; Pyrimidines; Receptors, Cholinergic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Impact of gender on statin efficacy.
Topics: Age Distribution; Aged; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Male; Middle Aged; Odds Ratio; Pravastatin; Probability; Prognosis; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Severity of Illness Index; Sex Distribution; Simvastatin; Survival Analysis; Treatment Outcome | 2007 |
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.
Topics: Clinical Trials as Topic; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Topics: Anticholesteremic Agents; Cardiovascular System; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipoproteins; Lovastatin; Pravastatin; Simvastatin | 1995 |
[HMG-CoA reductase inhibitor, pravastatin].
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Organ Specificity; Pravastatin; Species Specificity | 1993 |
Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy.
Topics: Adult; Aged; Cholesterol; Double-Blind Method; Humans; Hyperlipidemias; Middle Aged; Nephrotic Syndrome; Pravastatin; Prospective Studies | 1993 |
Treatment of lipids. Implications for the general practitioner.
Topics: Family Practice; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.
Topics: Anticholesteremic Agents; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Postoperative Complications; Pravastatin; Registries; Simvastatin; Treatment Outcome | 1996 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1997 |
The effect of HMG-CoA reductase inhibitors on chronic allograft rejection.
Topics: Clinical Trials as Topic; Graft Rejection; Graft Survival; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppressive Agents; Kidney Transplantation; Lipids; Pravastatin; Transplantation, Homologous | 1997 |
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Diabetes Complications; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Tolerance; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Simvastatin | 1997 |
Risk factor modification: rationale for management of dyslipidemia.
Topics: Anticholesteremic Agents; Canada; Controlled Clinical Trials as Topic; Coronary Disease; Humans; Hyperlipidemias; Pravastatin; Regression Analysis; Risk Factors; Scandinavian and Nordic Countries; United States | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Biochemical and molecular approaches for production of pravastatin, a potent cholesterol-lowering drug.
Topics: Animals; Fermentation; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Models, Chemical; Penicillium; Pravastatin; Streptomyces; Technology, Pharmaceutical | 1996 |
[Hyperlipidemia following heart transplantation. Pathogenic mechanisms and treatment].
Topics: Arteriosclerosis; Cholesterol, VLDL; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Postoperative Complications; Pravastatin; Preoperative Care | 1999 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Hemorheology and tissue oxygenation in hypertensives with lipoidoproteinosis and peripheral occlusive arterial disease (POAD) treated with sulodexide and pravastatine and evaluated with laser assisted optical rotational red cell analyzer (LORCA) and trans
Topics: Adult; Aged; Blood Gas Monitoring, Transcutaneous; Female; Glycosaminoglycans; Hemorheology; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Laser-Doppler Flowmetry; Lasers; Lipoid Proteinosis of Urbach and Wiethe; Male; Middle Aged; Peripheral Vascular Diseases; Pravastatin | 1999 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
[Secondary prevention of coronary artery disease with lipid-lowering drugs].
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Cause of Death; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Morbidity; Myocardial Revascularization; Patient Selection; Pravastatin; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
[Cholesterin synthase inhibition and atherosclerosis].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; CCAAT-Enhancer-Binding Proteins; Cholesterol; Cholesterol, LDL; Coenzyme A Ligases; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Synthase; Hyperlipidemias; Pravastatin; Pyridines; Randomized Controlled Trials as Topic; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pravastatin | 1992 |
Clinical implications of new drugs for lowering plasma cholesterol concentrations.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1991 |
76 trial(s) available for pravastatin and Hyperlipemia
| Article | Year |
|---|---|
Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS.
Topics: Cerebral Infarction; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intracranial Thrombosis; Japan; Male; Middle Aged; Pravastatin; Risk Assessment; Secondary Prevention; Stroke, Lacunar | 2020 |
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
Topics: Aged; Coronary Disease; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Prospective Studies; Renal Insufficiency, Chronic; Survival Rate; Time Factors; Treatment Outcome; United States | 2013 |
Which lipid measurement should we monitor? An analysis of the LIPID study.
Topics: Acute Coronary Syndrome; Adult; Aged; Australia; Female; Finland; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Longitudinal Studies; Male; Mass Screening; Middle Aged; New Zealand; Pravastatin | 2014 |
Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Topics: Aged; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Prospective Studies; Quinolines; Triglycerides | 2014 |
Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia.
Topics: Aged; Cholesterol; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Quinolines | 2016 |
Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Fatty Alcohols; Humans; Hyperlipidemias; Lipoproteins; Polymorphism, Single Nucleotide; Pravastatin | 2016 |
The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study: Rationale and Trial Protocol.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Carotid Arteries; Carotid Intima-Media Thickness; Clinical Protocols; Female; Follow-Up Studies; Humans; Hyperlipidemias; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Pravastatin; Recurrence; Statistics, Nonparametric; Stroke; Ultrasonography | 2017 |
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin | 2008 |
Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
Topics: Aged; Biological Products; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Life Style; Male; Middle Aged; Muscle Strength; Muscular Diseases; Pravastatin; Recurrence; Treatment Outcome | 2010 |
Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
Topics: Aged; Apolipoproteins; Belgium; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Poland; Pravastatin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Triglycerides | 2010 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2011 |
Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2011 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Effect of eicosapentaenoic acid on central systolic blood pressure.
Topics: Blood Pressure; Eicosapentaenoic Acid; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Pravastatin | 2013 |
Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
Topics: Adult; Cholesterol; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Topics: Adult; Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2002 |
Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia.
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Treatment Outcome | 2003 |
The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Atenolol; Benzopyrans; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hyperlipidemias; Hypertension; Male; Nebivolol; Pilot Projects; Pravastatin | 2003 |
Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins C; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperlipidemias; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Time Factors | 2003 |
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Fasting; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Stroke; Treatment Outcome | 2003 |
Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness.
Topics: Adult; Aged; Biomarkers; Blotting, Western; Cross-Over Studies; Electrocardiography, Ambulatory; Female; GTP-Binding Protein alpha Subunit, Gi2; GTP-Binding Protein alpha Subunits, Gi-Go; Heart Rate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lymphocytes; Male; Middle Aged; Parasympathetic Nervous System; Pravastatin; Predictive Value of Tests; Proto-Oncogene Proteins; Simvastatin; Single-Blind Method | 2003 |
Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound.
Topics: Aged; Body Mass Index; Carotid Arteries; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyridines; Tunica Media; Ultrasonography | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
Topics: Amides; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Esters; Female; Glycoproteins; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Placebos; Pravastatin; Sulfhydryl Compounds; Treatment Outcome | 2005 |
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides | 2005 |
Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Female; Humans; Hyperlipidemias; Intercellular Adhesion Molecule-1; Male; Pravastatin; Solubility; Stroke; Triglycerides | 2005 |
Biomarkers of inflammation and progression of chronic kidney disease.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Disease Progression; Etanercept; Female; Humans; Hyperlipidemias; Immunoglobulin G; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Myocardial Infarction; Pravastatin; Receptors, Tumor Necrosis Factor | 2005 |
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bezafibrate; Cyclopropanes; Female; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Nevirapine; Oxazines; Pravastatin; Protease Inhibitors; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound.
Topics: Aged; Atorvastatin; Coronary Stenosis; Drug Administration Schedule; Echocardiography, Three-Dimensional; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Reproducibility of Results; Ultrasonography, Interventional | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
Topics: Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin | 2005 |
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Treatment Outcome | 2005 |
[Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Inflammation Mediators; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Single-Blind Method | 2005 |
Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Interleukin-6; Lipids; Male; Middle Aged; Pravastatin; Time Factors; Treatment Outcome | 2006 |
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Topics: Adaptation, Physiological; Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Prospective Studies; Pyrroles; Risk Factors; Single-Blind Method; Triglycerides; Ultrasonography, Interventional; Vasculitis | 2006 |
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment.
Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles | 2007 |
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
Topics: Administration, Oral; Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; C-Reactive Protein; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome; Triglycerides | 1994 |
Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Apolipoproteins E; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Triglycerides | 1995 |
Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination.
Topics: Absorption; Apolipoproteins; Cholestanol; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipoproteins; Male; Middle Aged; Pravastatin; Squalene; Sterols; Triglycerides | 1995 |
Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.
Topics: Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Male; Middle Aged; Pravastatin | 1994 |
[A comparison between lovastatin and pravastatin--effects on lipids, sleep and quality of life in primary hyperlipidemia].
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Hyperlipidemias; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Quality of Life; Sleep | 1994 |
Pravastatin administration to hyperlipidemia in patients with nephrotic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hyperlipidemias; Male; Middle Aged; Nephrosis, Lipoid; Pravastatin | 1993 |
Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy.
Topics: Adult; Aged; Cholesterol; Double-Blind Method; Humans; Hyperlipidemias; Middle Aged; Nephrotic Syndrome; Pravastatin; Prospective Studies | 1993 |
[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
Topics: Anticholesteremic Agents; Drug Tolerance; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Pravastatin; Simvastatin | 1995 |
Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Double-Blind Method; Humans; Hyperlipidemias; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pravastatin; Time Factors; Triglycerides | 1995 |
Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Captopril; Combined Modality Therapy; Diuretics; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pravastatin; Prospective Studies; Sodium Chloride Symporter Inhibitors | 1995 |
West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Pravastatin; Risk; Scotland | 1996 |
The effect of pravastatin in patients with primary hyperlipidaemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Humans; Hyperlipidemias; Middle Aged; Pravastatin | 1995 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Child; Family; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pedigree; Pravastatin | 1997 |
[Risk factors in elderly patients selected by primary care physicians for hypolipemic treatment].
Topics: Age Factors; Aged; Anticholesteremic Agents; Cholesterol; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 1996 |
Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pravastatin; Triglycerides | 1997 |
Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrazines | 1997 |
Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Humans; Hyperlipidemias; Middle Aged; Niacin; Pravastatin; Risk Factors; Triglycerides | 1997 |
Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study.
Topics: Cholesterol; Cholesterol, LDL; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Middle Aged; Postmenopause; Pravastatin; Prospective Studies | 1998 |
Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gingival Hyperplasia; Hirsutism; Humans; Hyperlipidemias; Immunosuppressive Agents; Indoles; Kidney Transplantation; Lovastatin; Male; Middle Aged; Pravastatin; Tacrolimus | 1998 |
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Topics: Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Acids, Unsaturated; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1998 |
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Creatine; Creatine Kinase; Drug Therapy, Combination; Female; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver Function Tests; Male; Middle Aged; Pravastatin; Retrospective Studies; Safety; Treatment Outcome; Triglycerides | 1999 |
Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.
Topics: Aged; Aspirin; Blood Coagulation Factors; Cholesterol, LDL; Coronary Thrombosis; Double-Blind Method; Female; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein(a); Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 1999 |
Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Topics: Adult; Cyclosporine; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Male; Pravastatin; Simvastatin | 1999 |
The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group.
Topics: Blood Urea Nitrogen; Calcium Channel Blockers; Cholesterol; Creatinine; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Kidney Diseases; Male; Middle Aged; Pravastatin; Treatment Outcome | 1999 |
Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Topics: Adult; Anticholesteremic Agents; Drug Tolerance; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Pilot Projects; Pravastatin; Ritonavir; Saquinavir; Treatment Outcome | 2000 |
Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension.
Topics: Echocardiography; Female; Heart Ventricles; Hemodynamics; Humans; Hyperlipidemias; Hypertension; Linear Models; Male; Middle Aged; Pravastatin | 2000 |
Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause.
Topics: Arteriosclerosis; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Japan; Lipids; Menopause; Middle Aged; Pravastatin | 2000 |
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia.
Topics: Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Female; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Transplantation; Lipids; Male; Middle Aged; Pravastatin; Time Factors | 2001 |
Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine.
Topics: Adenosine; Aminophylline; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Disease; Electrocardiography; Female; Hemodynamics; Humans; Hyperlipidemias; Lactates; Male; Middle Aged; Myocardial Ischemia; Pravastatin | 2001 |
Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2001 |
A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
Topics: Adult; Drug Administration Schedule; Fasting; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lipoproteins, LDL; Particle Size; Pravastatin; Triglycerides | 2002 |
[Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Japan; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome | 2002 |
A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia.
Topics: Adolescent; Child; Colestipol; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Patient Compliance; Patient Selection; Pravastatin; Treatment Outcome | 2002 |
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pravastatin | 1992 |
Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
Topics: Adult; Aged; Apolipoproteins; Drug Evaluation; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Nephrotic Syndrome; Pravastatin | 1992 |
97 other study(ies) available for pravastatin and Hyperlipemia
| Article | Year |
|---|---|
Statin Effects on Vascular Calcification: Microarchitectural Changes in Aortic Calcium Deposits in Aged Hyperlipidemic Mice.
Topics: Age Factors; Animals; Aorta; Aortic Diseases; Atherosclerosis; Calcium; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Pravastatin; Rupture, Spontaneous; Time Factors; Vascular Calcification | 2021 |
Pravastatin improves atherosclerosis in mice with hyperlipidemia by inhibiting TREM-1/DAP12.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Hyperlipidemias; Interleukin-1; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pravastatin; Triggering Receptor Expressed on Myeloid Cells-1; Tumor Necrosis Factor-alpha | 2018 |
PRavastatin Versus FlUVastatin After Statin Intolerance: The PRUV-Intolerance Study With Propensity Score Matching.
Topics: Aged; Biomarkers; Creatine Kinase; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Pravastatin; Propensity Score; Retrospective Studies; Risk Factors | 2019 |
[Dermatomyositis].
Topics: Aged; Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Citalopram; Depression; Dermatomyositis; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Pravastatin | 2013 |
Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARγ expression and activating Wnt signaling pathway.
Topics: Adipogenesis; Adipose Tissue; Adrenal Cortex Hormones; Animals; beta Catenin; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Femur Head; Femur Head Necrosis; Fibrinolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Low Density Lipoprotein Receptor-Related Protein-5; Male; Methylprednisolone; Neovascularization, Physiologic; Osteogenesis; Osteonecrosis; PPAR gamma; Pravastatin; Rats; Rats, Wistar; Wnt Signaling Pathway; Wnt3A Protein | 2014 |
Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk Factors; Simvastatin; Sweden | 2016 |
Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity.
Topics: Acidosis; Adult; Animals; Cell Line; Chylomicron Remnants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Male; Mice; Models, Biological; Muscular Diseases; Pravastatin; Simvastatin | 2017 |
Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway.
Topics: Acute Kidney Injury; Animals; Apolipoproteins E; Cholesterol; Creatinine; Enzyme Inhibitors; Farnesyltranstransferase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney; Male; Methionine; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mice, Knockout; Pravastatin; Reperfusion Injury; Terpenes | 2008 |
Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease.
Topics: Anticholesteremic Agents; Coronary Artery Bypass; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrimidines; Radiography; Rosuvastatin Calcium; Saphenous Vein; Sulfonamides; Ultrasonography; Vascular Diseases | 2009 |
Statins and colorectal cancer: the jury is still out.
Topics: Age Factors; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Male; Needs Assessment; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate | 2009 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
Topics: Adult; Aged; Clinical Trials, Phase III as Topic; Databases, Factual; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Time Factors | 2012 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
Pravastatin inhibits plaque rupture and subsequent thrombus formation in atherosclerotic rabbits with hyperlipidemia.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Aorta; Aorta, Abdominal; Atherosclerosis; Cholesterol; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Histamine; Hyperlipidemias; Male; Plaque, Atherosclerotic; Pravastatin; Rabbits; Thrombosis; Thromboxane B2; Triglycerides; Viper Venoms | 2013 |
Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Coagulation Factors; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Fibrinolysis; Humans; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Platelet Aggregation Inhibitors; Pravastatin; Statistics, Nonparametric; Treatment Outcome | 2000 |
[Utility of pravastin in cardiac transplant dyslipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppressive Agents; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2002 |
The lower the LDL, the better.
Topics: Academies and Institutes; Atorvastatin; Heptanoic Acids; Human Experimentation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance Coverage; Insurance, Health; Lipoproteins, LDL; Pravastatin; Pyrroles | 2002 |
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Drug Therapy, Combination; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Risk Factors; Treatment Outcome | 2002 |
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hyperlipidemias; Male; Middle Aged; Postprandial Period; Pravastatin; Severity of Illness Index | 2002 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies | 2003 |
Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Tomography, Emission-Computed, Single-Photon | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans.
Topics: Adult; Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Apolipoproteins E; Cholesterol; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin | 2003 |
Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
Topics: Adult; Anticholesteremic Agents; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pravastatin; Treatment Outcome | 2003 |
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E | 2003 |
Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits.
Topics: Animals; Benzoates; Cholesterol; Homozygote; Hydroxybenzoate Ethers; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Pravastatin; Pyrrolidinones; Rabbits; Triglycerides | 2004 |
AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cholesterol, VLDL; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Male; Olmesartan Medoxomil; Pravastatin; Proteinuria; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Renal Insufficiency; Tetrazoles; Triglycerides | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
Topics: Adolescent; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hyperlipidemias; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Reversal of atherosclerosis with aggressive lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hyperlipidemias; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
Topics: Aged; Antioxidants; Cholestenes; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Erythrocyte Membrane; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Indoles; Male; Middle Aged; Oxidative Stress; Pravastatin; Prospective Studies; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atherosclerosis; Blood Pressure; Chemokine CCL2; Cholesterol; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Immunohistochemistry; Macrophages; Olmesartan Medoxomil; Pravastatin; Rabbits; Tetrazoles; Tunica Intima | 2005 |
The long-term course of low-density lipoprotein cholesterol after initiation of statin treatment: retrospective database analysis over 3 years in health maintenance organization enrollees.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Data Interpretation, Statistical; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Maintenance Organizations; Humans; Hyperlipidemias; Indoles; Long-Term Care; Male; Middle Aged; Pravastatin; Retrospective Studies; Time Factors | 2005 |
Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins.
Topics: Animals; Aorta; Aortic Diseases; Cells, Cultured; Cholesterol; Down-Regulation; Female; Gene Expression Regulation; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Muscle, Smooth, Vascular; NF-kappa B; Pravastatin; Rabbits; Scavenger Receptors, Class E | 2006 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Triglycerides | 2007 |
A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Cohort Studies; Female; Fish Oils; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Coronary Vessels; Hyperlipidemias; Hyperplasia; Macrophages; Muscle, Smooth, Vascular; Pravastatin; Rabbits | 1995 |
[Treatment of hyperlipidemia in obese patients: monotherapy versus bi-therapy].
Topics: Adult; Bezafibrate; Cholesterol; Cholesterol, HDL; Drug Evaluation; Drug Therapy, Combination; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Pravastatin; Triglycerides | 1995 |
Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation.
Topics: Adult; Cholesterol; Cholesterol, LDL; Creatinine; Female; Hemoglobins; Humans; Hyperlipidemias; Leukocyte Count; Male; Pancreas Transplantation; Platelet Count; Pravastatin; Triglycerides | 1994 |
Safety of combined pravastatin-gemfibrozil therapy.
Topics: Cholesterol, LDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Pravastatin | 1994 |
Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Injections, Intravenous; Lipids; Lipoproteins; Lipoproteins, VLDL; Liver; Male; Particle Size; Polyethylene Glycols; Pravastatin; Rabbits | 1994 |
Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.
Topics: Adolescent; Blood Component Removal; Combined Modality Therapy; Drug Resistance; Glomerulosclerosis, Focal Segmental; Humans; Hyperlipidemias; Immunosuppressive Agents; Kidney Function Tests; Lipoproteins, LDL; Male; Nephrotic Syndrome; Pravastatin | 1993 |
Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Male; Middle Aged; Patient Selection; Pravastatin; Retrospective Studies; Treatment Outcome | 1996 |
[Prevention of coronary disease using pravastatin in men with hyperlipidemia].
Topics: Coronary Disease; Humans; Hyperlipidemias; Male; Pravastatin | 1996 |
Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Lipids; Liver Transplantation; Male; Middle Aged; Pravastatin; Prospective Studies | 1996 |
[Disorders of lipid metabolism and renal failure--what is cause, what is sequelae?].
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Kidney Transplantation; Postoperative Complications; Pravastatin | 1996 |
Effects of low-dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year.
Topics: Animals; Aortic Diseases; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Coronary Disease; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Heterozygote; Hyperlipidemias; Male; Pravastatin; Rabbits; Time Factors | 1997 |
[Care Study. Secondary prevention after myocardial infarct in moderately elevated total cholesterol].
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Humans; Hyperlipidemias; Myocardial Infarction; Pravastatin; Risk Factors; Survival Rate | 1997 |
Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin | 1997 |
[Coronary mortality lowered by 24%. Convincing results of the LIPID Study on Secondary Prevention].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Myocardial Ischemia; Pravastatin | 1998 |
Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet.
Topics: Animals; Aorta; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Drug Therapy, Combination; Female; Hyperlipidemias; Immunohistochemistry; Liver; Male; Pravastatin; Probucol; Rabbits; Survival Rate; Treatment Outcome | 1998 |
Possible recurrence of primary sclerosing cholangitis following living-related liver transplantation: report of a case.
Topics: Adult; Cholagogues and Choleretics; Cholangiography; Cholangitis, Sclerosing; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver Transplantation; Living Donors; Magnetic Resonance Imaging; Male; Mothers; Pravastatin; Recurrence; Ursodeoxycholic Acid | 1998 |
[Treatment with pravastatin of dyslipidemia associated with diabetic nephropathy].
Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin | 1998 |
Statins and C-reactive protein.
Topics: C-Reactive Protein; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Dietary Services; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Time Factors; Treatment Refusal; Triglycerides | 2000 |
[Antilipemic agents, hypothyroidism, and rhabdomyolysis].
Topics: Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Middle Aged; Pravastatin; Rhabdomyolysis | 2000 |
Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits.
Topics: Animals; Anticholesteremic Agents; Antimetabolites; Ascorbic Acid; Buthionine Sulfoximine; Cholesterol; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Kidney; Liver; Male; Oxidation-Reduction; Phospholipids; Pravastatin; Rabbits; Thiobarbituric Acid Reactive Substances; Triglycerides | 2000 |
[Socioeconomic aspects of therapy of cardiovascular diseases].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Cost-Benefit Analysis; Costs and Cost Analysis; Female; Health Priorities; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Primary Prevention; Prognosis; Risk Factors; Socioeconomic Factors | 2000 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2000 |
Diabetic retinopathy and serum lipids.
Topics: Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Diabetic Retinopathy; Disease Progression; Exudates and Transudates; Female; Humans; Hyperlipidemias; Laser Coagulation; Lipoproteins, LDL; Pravastatin; Triglycerides | 2000 |
Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gonadal Steroid Hormones; Humans; Hyperlipidemias; Longitudinal Studies; Menopause; Middle Aged; Pravastatin; Triglycerides | 2001 |
Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Arteriosclerosis; Azo Compounds; Cell Division; Cells, Cultured; Collagen; Coloring Agents; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Indoles; Lipids; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Muscle, Smooth; Pravastatin; Procollagen; Rabbits; RNA, Messenger | 2001 |
Dementia and statins.
Topics: Aged; Aged, 80 and over; Dementia; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Pravastatin; Tumor Necrosis Factor-alpha | 2001 |
Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
Topics: Adolescent; Adult; Child; Cyclosporine; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppression Therapy; Immunosuppressive Agents; Lipids; Male; Pravastatin; Retrospective Studies; Tacrolimus; Transaminases | 2001 |
Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?
Topics: Aged; Anticholesteremic Agents; Apolipoproteins E; Bezafibrate; Biomarkers; Butyrylcholinesterase; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Linear Models; Male; Phenotype; Pravastatin; Triglycerides | 2001 |
Diabetes, statins and cardiovascular disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Humans; Hyperlipidemias; Pravastatin | 2001 |
Shoulder stiffness: a common adverse effect of HMG-CoA reductase inhibitors in women?
Topics: Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Sex Factors; Shoulder Joint; Shoulder Pain | 2001 |
Hyperlipidaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperlipidemias; Lovastatin; Nitric Oxide; Pravastatin; Rabbits; Simvastatin | 2001 |
Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol.
Topics: Aged; Anticholesteremic Agents; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Hospitals, Veterans; Humans; Hyperlipidemias; Male; Middle Aged; Pharmacy Service, Hospital; Pravastatin; Prospective Studies; Risk Factors; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
Topics: Adult; Aged; Aged, 80 and over; Australia; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance, Pharmaceutical Services; Male; Middle Aged; Models, Econometric; Monte Carlo Method; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2001 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
Statin use, hyperlipidaemia, and the risk of breast cancer.
Topics: Aged; Anticholesteremic Agents; Breast Neoplasms; Case-Control Studies; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Middle Aged; Pravastatin; Risk Factors | 2002 |
Immunosuppressive effects of statins.
Topics: Adjuvants, Immunologic; Cells, Cultured; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interferon-gamma; Lovastatin; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
[Treatment of hyperlipidemia].
Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dietary Fiber; Energy Intake; Female; Humans; Hyperlipidemias; Male; Niceritrol; Pravastatin; Probucol | 1992 |
Assessment of functional low-density-lipoprotein receptors on lymphocytes by a simplified method using culture medium with lipoprotein-free fetal calf serum and pravastatin.
Topics: Adult; Cells, Cultured; Cholesterol; Culture Media; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, LDL; Lymphocytes; Male; Pravastatin; Receptors, Cell Surface; Receptors, Lipoprotein; Triglycerides | 1992 |
Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits.
Topics: Absorption; Acyl Coenzyme A; Animals; Cholesterol; Hyperlipidemias; Intestinal Mucosa; Liver; Pravastatin; Rabbits; Sterol O-Acyltransferase; Time Factors | 1992 |
Early experience with pravastatin in South African patients with type II hyperlipidaemia.
Topics: Adult; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; South Africa | 1992 |
[Diabetes mellitus and hyperlipidemia].
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin; Pravastatin | 1992 |
Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits.
Topics: Adrenal Glands; Animals; Cholesterol, LDL; Cholestyramine Resin; Drug Synergism; Hyperlipidemias; Intestinal Mucosa; Intestines; Liver; Male; Pravastatin; Rabbits; Receptors, LDL; RNA, Messenger | 1992 |
Decreased albuminuria by pravastatin in hyperlipidemic diabetics.
Topics: Aged; Albuminuria; Diabetic Nephropathies; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin | 1991 |
Pravastatin decreases serum lipids and vascular cholesterol deposition in Watanabe heritable hyperlipidemic (WHHL) rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Coronary Vessels; Hydroxyproline; Hyperlipidemias; Lipids; Pravastatin; Rabbits; Receptors, LDL; Triglycerides | 1991 |
[Hyperlipidemia and drug treatment].
Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidney Failure, Chronic; Niceritrol; Pantetheine; Pravastatin; Probucol; Vitamin E | 1991 |
Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Bile; Bile Acids and Salts; Fatty Acids; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipid Metabolism; Lipids; Male; Middle Aged; Naphthalenes; Pravastatin | 1991 |
The effects of lipid lowering on diabetic retinopathy.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Dietary Fats; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Triglycerides; Visual Acuity | 1991 |
Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
Topics: Animals; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kinetics; Lipoproteins, VLDL; Male; Naphthalenes; Nephrosis; Pravastatin; Puromycin; Rats; Rats, Inbred Strains; Triglycerides | 1990 |
Treating hyperlipidemia, Part III: Drug therapy.
Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Pravastatin | 1987 |
CS-514 suppresses plasma triglyceride in hypertriglyceridemic subjects without modifying a lipoprotein structural model.
Topics: Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Male; Middle Aged; Models, Structural; Naphthalenes; Pravastatin; Triglycerides | 1987 |